- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Australian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
37
Companies with a Value score of at least 3, ordered by Value score
37 companies
Trajan Group Holdings
Market Cap: AU$106.8m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.68
7D
-8.7%
1Y
-40.9%
CSL
Market Cap: AU$87.2b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$180.99
7D
1.3%
1Y
-33.6%
CSL
Market Cap: AU$87.2b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$180.08
7D
1.1%
1Y
-33.6%
Aroa Biosurgery
Market Cap: AU$236.3m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.69
7D
-10.5%
1Y
8.7%
Trajan Group Holdings
Market Cap: AU$106.8m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.65
7D
-5.8%
1Y
-36.6%
Medical Developments International
Market Cap: AU$63.1m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.56
7D
-1.8%
1Y
30.2%
Telix Pharmaceuticals
Market Cap: AU$4.8b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.19
7D
-7.3%
1Y
-37.6%
Medical Developments International
Market Cap: AU$63.1m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.51
7D
-8.1%
1Y
20.0%
Telix Pharmaceuticals
Market Cap: AU$4.8b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.06
7D
-10.0%
1Y
-38.9%
EZZ Life Science Holdings
Market Cap: AU$114.2m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.42
7D
0.4%
1Y
-14.8%
Immutep
Market Cap: AU$412.1m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.28
7D
7.7%
1Y
-12.5%
Radiopharm Theranostics
Market Cap: AU$64.0m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.022
7D
-8.3%
1Y
-18.5%
Mesoblast
Market Cap: AU$3.0b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.32
7D
1.3%
1Y
46.8%
Vita Life Sciences
Market Cap: AU$131.6m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.40
7D
0%
1Y
14.3%
Avecho Biotechnology
Market Cap: AU$19.0m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.
AVE
AU$0.006
7D
0%
1Y
100.0%
Little Green Pharma
Market Cap: AU$39.7m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
1.9%
1Y
-1.9%
Mayne Pharma Group
Market Cap: AU$305.4m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYXDA
AU$3.47
7D
-9.4%
1Y
n/a
Immutep
Market Cap: AU$412.1m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.28
7D
5.8%
1Y
-14.1%
Avecho Biotechnology
Market Cap: AU$19.0m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.
AVE
AU$0.006
7D
0%
1Y
100.0%
Little Green Pharma
Market Cap: AU$39.7m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.0%
Radiopharm Theranostics
Market Cap: AU$64.0m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.022
7D
-8.3%
1Y
-18.5%
Neuren Pharmaceuticals
Market Cap: AU$2.4b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$18.40
7D
-1.8%
1Y
24.3%
Aroa Biosurgery
Market Cap: AU$236.3m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.65
7D
-16.7%
1Y
0%
EZZ Life Science Holdings
Market Cap: AU$114.2m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.44
7D
-2.8%
1Y
-15.1%
Mayne Pharma Group
Market Cap: AU$305.4m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYXDA
AU$3.54
7D
-9.2%
1Y
n/a
Vita Life Sciences
Market Cap: AU$131.6m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.45
7D
0%
1Y
17.2%
Mesoblast
Market Cap: AU$3.0b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.28
7D
-1.3%
1Y
42.1%
Clinuvel Pharmaceuticals
Market Cap: AU$558.2m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.85
7D
-3.0%
1Y
-20.3%
Alterity Therapeutics
Market Cap: AU$97.9m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.01
7D
11.1%
1Y
233.3%
AVITA Medical
Market Cap: AU$114.3m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
AVH
AU$1.13
7D
-3.8%
1Y
-69.7%
AVITA Medical
Market Cap: AU$117.7m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
AVH
AU$1.13
7D
-3.0%
1Y
-70.2%
Paradigm Biopharmaceuticals
Market Cap: AU$150.0m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.35
7D
-9.1%
1Y
42.9%
Neuren Pharmaceuticals
Market Cap: AU$2.4b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$18.78
7D
0.9%
1Y
19.5%
Clinuvel Pharmaceuticals
Market Cap: AU$558.2m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.09
7D
0.09%
1Y
-18.2%
Genetic Signatures
Market Cap: AU$67.0m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.29
7D
-13.4%
1Y
-59.7%
Genetic Signatures
Market Cap: AU$67.0m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.28
7D
-9.5%
1Y
-59.6%